Article
The Federal Circuit’s Recent "Safe Harbor" Ruling Could Impact Biosimilars Drug Development
A recent Federal Circuit case, Momenta v. Amphastar, involves the Hatch-Waxman 271(e)(1) safe harbor, and is rousing the biologics and biosimilars industry.
Drinker Biddle & Reath LLP
